Armata Pharmaceuticals (ARMP) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Armata Pharmaceuticals (ARMP) has outperformed Voyager Therapeutics (VYGR) over the past year, losing 56.9% versus a loss of 63.4%. Over five years, ARMP leads with a -42.0% price change compared with -50.0% for VYGR. Armata Pharmaceuticals is the larger company by market cap ($112.7 million vs $95.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARMP | VYGR |
|---|---|---|
| Share price | $3.03 | $1.53 |
| Market cap | $112.69M | $95.21M |
| 1-day change | +1.68% | -4.97% |
| YTD return | -51.75% | -61.07% |
| 1-year return | -56.90% | -63.40% |
| 5-year return | -41.95% | -50.00% |
| EPS (TTM) | $-4.17 | $-1.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $40.37M |
| Revenue growth (YoY) | — | -49.53% |
| Net income (latest FY) | $-173.80M | $-119.72M |
| Operating margin | — | -326.56% |
| Net margin | — | -296.53% |
| 52-week high | $14.98 | $5.48 |
| 52-week low | $2.40 | $1.48 |
| Distance from 52-week high | -79.77% | -72.08% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +477.56% | +829.41% |
| Average volume | 182.52K | 770.24K |
| Shares outstanding | 37.19M | 62.23M |
| Employees | 61 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Armata Pharmaceuticals
ARMP stock →Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 61 employees
About Voyager Therapeutics
VYGR stock →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
ARMP vs VYGR FAQ
Which is bigger, Armata Pharmaceuticals or Voyager Therapeutics?
Armata Pharmaceuticals (ARMP) is larger, with a market capitalization of $112.69M compared with $95.21M for Voyager Therapeutics (VYGR).
Which stock has performed better over the past year, ARMP or VYGR?
ARMP returned -56.90% over the past 12 months, compared with -63.40% for VYGR (price return, excluding dividends). Past performance does not predict future results.
Are Armata Pharmaceuticals and Voyager Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.